Stock Financial Ratios, Dividends, Split History

IIVI / II-VI Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,660.05
Enterprise Value ($M)2,888.37
Book Value ($M)1,015.17
Book Value / Share16.23
Price / Book2.76
NCAV ($M)24.08
NCAV / Share0.39
Price / NCAV121.02
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 64,507,000
Common Shares Outstanding 63,279,520
Weighted Average Number Of Shares Outstanding Basic 62,576,000
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.08
Return on Assets (ROA)0.08
Return on Equity (ROE)0.12
Balance Sheet (mrq) ($M)
Quick Ratio2.45
Current Ratio3.68
Income Statement (mra) ($M)
Operating Income115.54
Net Income95.27
Earnings Per Share Diluted1.48
Earnings Per Share Basic1.52
Cash Flow Statement (mra) ($M)
Cash From Operations118.62
Cash from Investing-177.24
Identifiers and Descriptors
Central Index Key (CIK)820318
Related CUSIPS
902104958 090210410 902104908

Split History

Stock splits are used by II-VI Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

RBC or IIVI: Which Is the Better Value Stock Right Now?

2018-06-11 zacks
Investors interested in stocks from the Manufacturing - Electronics sector have probably already heard of Regal Beloit (RBC - Free Report) and II-VI (IIVI - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. (6-0)

Lumentum Is Worth $80

2018-05-08 seekingalpha
Lumentum's (LITE) pre-earnings jitters proved short-lived when the stock fell to $50, only to recover in just a few trading sessions. The stock bounced back from two positive catalysts. First, the fear that Apple (AAPL) would report weak iPhone X sales proved wrong. Second, Lumentum's quarterly earnings profit, compared to a loss in the prior year, gave investors the optimism it needed. (12-0)

II-VI's (IIVI) CEO Chuck Mattera on Q3 2018 Results - Earnings Call Transcript

2018-05-01 seekingalpha
Good day, ladies and gentlemen. And welcome to the II-VI Incorporated Fiscal Year 2018 Quarter Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time [Operator Instructions]. As a reminder, this conference call is being recorded. (13-0)

II-VI Incorporated 2018 Q3 - Results - Earnings Call Slides

2018-05-01 seekingalpha
The following slide deck was published by II-VI Incorporated in conjunction with their 2018 Q3 earnings call. (1-0)

nLight - Laser-Focused IPO

2018-04-27 seekingalpha
Investors are attracted to strong growth and expanding margins, as the industry at large is doing very well at the moment. (15-0)

CUSIP: 902104108